Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 19Unknown 3Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 85Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia 24Recurrence 16Lymphoma 14Myelodysplastic Syndromes 13Burkitt Lymphoma 13Congenital Abnormalities 12Lymphoma, Non-Hodgkin 10Leukemia, Monocytic, Acute 10Leukemia, Myelomonocytic, Acute 8Leukemia, Erythroblastic, Acute 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Megakaryoblastic, Acute 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Multiple Myeloma 4Hematologic Neoplasms 4Blast Crisis 4Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Biphenotypic, Acute 3Anemia, Refractory, with Excess of Blasts 3Thrombocytopenia 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2

Interventions

tanespimycin 1entinostat 1eltrombopag 1alvocidib 1Sorafenib 1Mitoxantrone 1Idarubicin 1Etoposide 1Cytarabine 1Cilengitide 1Bortezomib 1Bevacizumab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Eosinophilic, Acute × Cytarabine × Clear all
NCT00096148 2013-01-24

Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
120 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡